Sort   by:  
 Page size 
ProteomicsMetabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis
Non-alcoholic fatty liver disease is now considered the most common form of chronic liver disease. It is a complex metabolic disease that silently progresses into non-alcoholic steatohepatitis (NASH). In fact, NASH is the tipping point for pericellular fibrosis, cirrhosis and hepatocellular carcinom...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-08-19 | MSV000088003 | MassIVE
ProteomicsGlycopeptide Biomarkers for HCC Detection in Patients with NASH
A comprehensive screening of site-specific N-glycopeptides in serum haptoglobin (Hp), a reporter molecule for aberrant glycosylation in HCC, has been performed to characterize glycopeptide markers for NASH-related HCCs.
ORGANISM(S): Homo sapiens (Human) 
2020-05-22 | PXD018502 | Pride
Human Serum Glycopeptide Lc-ethcd-ms/ms 
TranscriptomicsIncreased hemoglobin expression in NASH livers
BACKGROUND & AIMS: Recent studies revealed that hemoglobin is expressed in some non-erythrocytes and it suppresses oxidative stress when overexpressed. Oxidative stress plays a critical role in the pathogenesis of non-alcoholic steatohepatitis (NASH). This study was to investigate whether hemoglobin...
ORGANISM(S): Homo sapiens 
2010-10-20 | E-GEOD-24807 | biostudies-arrayexpress
TranscriptomicsHepatic transcriptomic changes during non-alcoholic steatohepatitis (NASH)-associated liver carcinogenesis in mice
Hepatocellular carcinoma (HCC), which accounts for 90% of all primary livers tumors, is the fourth most common cancer in the world. The development of HCC is a long-term and complex process, and uncovering the molecular mechanisms associated with HCC development is critical for the disease diagnosi...
ORGANISM(S): Mus musculus 
2016-06-22 | E-GEOD-83596 | biostudies-arrayexpress
TranscriptomicsGene expression profiles of livers and liver tumors from mice fed high-fat diet and high fructose-glucose solution for 52 weeks
The lack of a preclinical model of nonalcoholic steatohepatitis (NASH) and hepatocellular cancer (HCC) that recapitulates human disease is a major barrier to therapeutic development. We report a high fat-high sugar diet-induced NASH and HCC in a stable isogenic 129S1/SvImJ crossed with C57Bl/6J mice...
ORGANISM(S): Mus musculus 
2016-07-25 | E-GEOD-67679 | biostudies-arrayexpress
TranscriptomicsGene expression profiles of livers from mice fed high-fat diet and high fructose-glucose solution for 8 weeks
The lack of a preclinical model of nonalcoholic steatohepatitis (NASH) and hepatocellular cancer (HCC) that recapitulates human disease is a major barrier to therapeutic development. We report a high fat-high sugar diet-induced NASH and HCC in a stable isogenic 129S1/SvImJ crossed with C57Bl/6J mice...
ORGANISM(S): Mus musculus 
2016-07-25 | E-GEOD-67678 | biostudies-arrayexpress
TranscriptomicsTid1 Deficiency Disrupting Mitochondria to Drive NASH-Dependent Hepatocellular Carcinoma Progression
Non-alcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) is a significant risk factor for hepatocellular carcinoma (HCC). However, a preclinical model of progressive NAFLD/NASH is largely lacking. Here, we report that mice with hepatocyte-specific deletion of Tid1, encoding a mitochondrial coc...
ORGANISM(S): Mus musculus 
2022-06-02 | E-MTAB-9973 | biostudies-arrayexpress
GenomicsImmune-checkpoint blockade lacks anti-tumorgenicity in NASH-induced HCC
Immune-checkpoint blockade lacks anti-tumorgenicity in NASH-induced HCC
PRJNA671310 | ENA
ProteomicsPD-1-targeted immunotherapy in NASH-triggered liver cancer induces pro-tumorigenic environment through CD8+PD-1+ T-cells
Immunotherapy has opened hitherto unknown possibilities to treat cancer. Whereas some cancer types (e.g. melanoma) can be efficiently treated, others lack measurable positive effects (e.g. PDAC). Moreover, stratification of responders/non-responders is only possible in some cancer types (e.g. melano...
ORGANISM(S): Mus musculus (Mouse) 
2021-03-03 | PXD017236 | Pride
Immunotherapy Cd8+pd1+ Nash 
GenomicsEvaluating pre-clinical models for studying NASH driven HCC.
Evaluating pre-clinical models for studying NASH driven HCC.
PRJNA474086 | ENA
Sort   by:  
 Page size